The $230M IPO provides City Therapeutics with a multi-year cash runway to advance its three lead programs (CITY-FXI, CITY-RBP4, CITY-TFR2) through clinical proof-of-concept. Monitor for initial clinical data readouts and any subsequent pipeline prioritization updates.
Price Chart
Executive Summary
City Therapeutics closed its upsized IPO of 12,777,777 shares at $18.00 per share, raising approximately $230 million in gross proceeds. The IPO provides substantial cash runway for a clinical-stage RNAi biotech with three lead programs, but the company remains pre-revenue with no approved products.
Key Financial Metrics
Key Facts
- Upsized IPO of 12,777,777 shares at $18.00 per share
- Gross proceeds of approximately $230.0 million
- Underwriters exercised full option to purchase 1,666,666 additional shares
- Common stock began trading on Nasdaq on October 16, 2026 under ticker CTY
- Goldman Sachs, Jefferies, Stifel, and Oppenheimer acted as joint book-running managers
Financial Impact
Approximately $230 million gross proceeds raised, before underwriting discounts and expenses
Risk Factors
- Pre-revenue clinical-stage company with no approved products
- RNAi therapeutic space is competitive with established players like Alnylam
- Dilution from IPO shares may pressure near-term stock price
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383856 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | SC 13D | $20.79 | awaiting T+5 | — | $20.86 (+0.34%) |
Oct 26, 2026 1d ago | SC 13G | $20.79 | awaiting T+5 | — | $20.86 (+0.34%) |
Oct 22, 2026 5d ago | SC 13G | $20.77 | awaiting T+5 | — | $20.86 (+0.43%) |
Oct 19, 2026 8d ago | Insider Cluster | $20.83 $20.86 | ▲ +0.14% | ▲ +0.06% | $20.86 (+0.14%) |
Oct 19, 2026 8d ago | Press Release | $20.83 $21.19 | ▲ +1.73% | ▲ +1.70% | $20.86 (+0.14%) |
Oct 16, 2026 11d ago | 424B4 | $21.46 $20.79 | ▼ −3.12% | ▼ −2.98% | $20.86 (−2.80%) |
Oct 16, 2026 11d ago | EFFECT | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 12d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 12d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 12d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers